Skip to main content
Erschienen in: Tumor Biology 7/2014

01.07.2014 | Research Article

Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis

verfasst von: Jie Kang, Xian-Zhao Deng, You-Ben Fan, Bo Wu

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

We conducted the meta-analysis of all relevant case–control studies aiming to evaluate the relationships of common polymorphisms in forkhead box E1 (FOXE1) and ataxia telangiectasia mutated (ATM) genes to the risk of papillary thyroid carcinoma (PTC). A range of electronic databases were searched without language restrictions: Web of Science (1945 ~ 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 ~ 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013). This meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with their 95 % confidence interval (CI) were calculated. Eight case–control studies with 2,085 PTC patients and 10,341 healthy controls were included. Fourteen common polymorphisms were evaluated, including rs3758249 A > G, rs907577 G > A, rs1867277 G > A, rs3021526 C > T, rs1443434 G > T, rs907580 G > A, rs965513 A > G, rs944289 C > T, and rs189037 G > A polymorphisms in the FOXE1 gene and rs373759 G > A, rs4988099 A > G, rs1801516 G > A, rs664677 T > C, and rs609429 G > C polymorphisms in the ATM gene. Our results demonstrated that the FOXE genetic polymorphisms might be closely related to an increased risk of developing PTC under five genetic models (all P < 0.005), especially for rs3758249, rs907577, rs1867277, rs3021526, rs1443434, rs907580, rs704839, rs894673, and rs10119760 polymorphisms. Nevertheless, no positive associations were found between the ATM genetic polymorphisms and the development of PTC (all P > 0.05). The current meta-analysis provided evidence that FOXE1 genetic polymorphisms may contribute to increased PTC risk, especially for rs3758249, rs907577, rs1867277, rs3021526, rs1443434, rs907580, rs704839, rs894673, and rs10119760 polymorphisms. However, the ATM genetic polymorphisms may not be important dominants of susceptibility to PTC.
Literatur
1.
Zurück zum Zitat He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, et al. Srgap1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab. 2013;98(5):E973–80.PubMedCentralCrossRefPubMed He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, et al. Srgap1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab. 2013;98(5):E973–80.PubMedCentralCrossRefPubMed
2.
3.
Zurück zum Zitat Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764–73.CrossRefPubMed Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764–73.CrossRefPubMed
4.
Zurück zum Zitat Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8(3):155–65.CrossRefPubMed Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8(3):155–65.CrossRefPubMed
6.
Zurück zum Zitat Nikiforov YE. Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr Pathol. 2006;17(4):307–17.CrossRefPubMed Nikiforov YE. Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr Pathol. 2006;17(4):307–17.CrossRefPubMed
7.
Zurück zum Zitat Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, et al. Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. Int J Cancer. 2014;134(7):1659–68.CrossRefPubMed Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, et al. Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. Int J Cancer. 2014;134(7):1659–68.CrossRefPubMed
8.
Zurück zum Zitat Bullock M, Duncan EL, O’Neill C, Tacon L, Sywak M, Sidhu S, et al. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):E1814–9.CrossRefPubMed Bullock M, Duncan EL, O’Neill C, Tacon L, Sywak M, Sidhu S, et al. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):E1814–9.CrossRefPubMed
9.
Zurück zum Zitat Matsuse M, Takahashi M, Mitsutake N, Nishihara E, Hirokawa M, Kawaguchi T, et al. The FOXE1 and NKX2-1 LOCI are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet. 2011;48(9):645–8.CrossRefPubMed Matsuse M, Takahashi M, Mitsutake N, Nishihara E, Hirokawa M, Kawaguchi T, et al. The FOXE1 and NKX2-1 LOCI are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet. 2011;48(9):645–8.CrossRefPubMed
10.
Zurück zum Zitat Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Perez L, Schiavi F, Leskela S, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 2009;5(9):e1000637.PubMedCentralCrossRefPubMed Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Perez L, Schiavi F, Leskela S, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 2009;5(9):e1000637.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Gilbert F, Kauff N. Disease genes and chromosomes: disease maps of the human genome. Chromosome 9. Genet Test. 2001;5(2):157–74.CrossRefPubMed Gilbert F, Kauff N. Disease genes and chromosomes: disease maps of the human genome. Chromosome 9. Genet Test. 2001;5(2):157–74.CrossRefPubMed
12.
Zurück zum Zitat Bychkov A, Saenko V, Nakashima M, Mitsutake N, Rogounovitch T, Nikitski A, et al. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry. Thyroid. 2013;23(7):817–28.PubMedCentralCrossRefPubMed Bychkov A, Saenko V, Nakashima M, Mitsutake N, Rogounovitch T, Nikitski A, et al. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry. Thyroid. 2013;23(7):817–28.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Platzer M, Rotman G, Bauer D, Uziel T, Savitsky K, Bar-Shira A, et al. Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire atm gene. Genome Res. 1997;7(6):592–605.PubMed Platzer M, Rotman G, Bauer D, Uziel T, Savitsky K, Bar-Shira A, et al. Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire atm gene. Genome Res. 1997;7(6):592–605.PubMed
16.
Zurück zum Zitat Akulevich NM, Saenko VA, Rogounovitch TI, Drozd VM, Lushnikov EF, Ivanov VK, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Endocr Relat Cancer. 2009;16(2):491–503.CrossRefPubMed Akulevich NM, Saenko VA, Rogounovitch TI, Drozd VM, Lushnikov EF, Ivanov VK, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Endocr Relat Cancer. 2009;16(2):491–503.CrossRefPubMed
17.
Zurück zum Zitat Gu Y, Yu Y, Ai L, Shi J, Liu X, Sun H, et al. (2013) Association of the ATM gene polymorphisms with papillary thyroid cancer. Endocrine Gu Y, Yu Y, Ai L, Shi J, Liu X, Sun H, et al. (2013) Association of the ATM gene polymorphisms with papillary thyroid cancer. Endocrine
18.
Zurück zum Zitat Liu C, Jiang YX, Chen C, Sun CZ, Zhao M. Correlation of FOXE1 gene polymorphism with papilliary thyroid carcinoma in Yunnan China. Journal of Modern Oncology. 2013;9:1958–63. Liu C, Jiang YX, Chen C, Sun CZ, Zhao M. Correlation of FOXE1 gene polymorphism with papilliary thyroid carcinoma in Yunnan China. Journal of Modern Oncology. 2013;9:1958–63.
19.
Zurück zum Zitat Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, et al. Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. Int J Cancer. 2013 Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, et al. Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. Int J Cancer. 2013
20.
Zurück zum Zitat Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
21.
Zurück zum Zitat Zintzaras E, Ioannidis JP. Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed Zintzaras E, Ioannidis JP. Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed
22.
Zurück zum Zitat Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed
23.
Zurück zum Zitat Kallel R, Belguith-Maalej S, Akdi A, Mnif M, Charfeddine I, Galofre P, et al. Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma. Cancer Biomark. 2010;8(1):43–51.PubMed Kallel R, Belguith-Maalej S, Akdi A, Mnif M, Charfeddine I, Galofre P, et al. Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma. Cancer Biomark. 2010;8(1):43–51.PubMed
24.
Zurück zum Zitat Rodriguez W, Jin L, Janssens V, Pierreux C, Hick AC, Urizar E, et al. Deletion of the RNaseIII enzyme dicer in thyroid follicular cells causes hypothyroidism with signs of neoplastic alterations. PLoS One. 2012;7(1):e29929.PubMedCentralCrossRefPubMed Rodriguez W, Jin L, Janssens V, Pierreux C, Hick AC, Urizar E, et al. Deletion of the RNaseIII enzyme dicer in thyroid follicular cells causes hypothyroidism with signs of neoplastic alterations. PLoS One. 2012;7(1):e29929.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009;10(8):887–93.PubMedCentralCrossRefPubMed Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009;10(8):887–93.PubMedCentralCrossRefPubMed
Metadaten
Titel
Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis
verfasst von
Jie Kang
Xian-Zhao Deng
You-Ben Fan
Bo Wu
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1865-5

Weitere Artikel der Ausgabe 7/2014

Tumor Biology 7/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.